Appointment of Internal Auditor w.e.f 30.05.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Norris Medicines Ltd reported audited financial results for Q4 and FY26 ending March 31, 2026. Revenue grew 39.7% year-on-year to Rs. 813.20 lakhs (from Rs. 582.02 lakhs). However, the company reported a net loss of Rs. 28.06 lakhs for FY26, though significantly improved from the prior year's loss of Rs. 123.75 lakhs. The company appointed M/s. Dhiren Y Parikh & Co. as Internal Auditors for FY 2026-27. The statutory auditor issued an unmodified (unqualified) opinion, and there are no related party transactions. Total equity remains deeply negative at Rs. -1,514.80 lakhs.
The company's substantial revenue growth is offset by persistent losses and negative equity, indicating financial stress despite improvement. The appointment of a new internal auditor may signal strengthened governance. Shareholders should monitor if the company can achieve profitability and restore positive equity.